The third foundational entity of IMS, Inedis (Innovation in entrepreneurship in drug discovery), proposes actions to structure and accompany the creation of companies emerging from IMS programmes or partner teams. Inedis’s action consists first of all in ensuring a post-maturation stage by structuring and hosting (“open-lab” actions) the operational teams for companies emerging from IMS.
Inedis will mentor companies in their early stages by relying on existing structures (SEMIA, SATT, Biovalley France) and on their committee of external experts and a network of entrepreneurs.
The committee will play an active role in constructing Inedis’s mentoring plan, its business model, and the process of identifying key candidates for recruitment to these future IMS companies.
Support Inedis and its start-ups
The young companies emerging from public research need equity capital to transform their technological projects into a business model. Your support is essential if the start-ups are to continue the pre-clinical development of their therapeutic innovation and to develop novel drugs for tomorrow.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.